After the EU member has reached a deal with the IMF for helping Greece to over come its unsustainable debt problems, The market is focusing now on the debt position in the other members which have faced recently a downgrading of their debt rating such as Spain and Portugal which are still looking in better conditions than Greece and have not reached the point of the need of an inevitable aid to face their debts requirements through the financial markets in a normal way. We see now that the worries about spreading the debts problems in other countries in the euro area have just eased with the EU members looking for a certain joint rescue plan or European mechanism for solving these financial problems out to store confidence in the Euro zone financial stability outlook again which lightened the pressure on the single currency which reached 10 months low reaching 1.2367 last Tuesday amid concerns about the EU summit results and it is now trading above 1.34 having strong opening this week with a gap above 1.348 but it could not find a place above 1.35 versus the greenback but it is still well- supported above 1.342

The pressure on the single currency is accumulating on the increased market worries about Greece bankruptcy and the solid germane position from giving unwarranted financial support to Greece until now. The worries about spreading the debts problems in other countries in the euro area and downgrading their creditability are putting pressure on the single currency across the broad as the deficit to GDP ratio average is at 6% nearly right now, while it should be below 3% on Maastricht treaty of the Euro area with no joint certain rescue plan or European mechanism until for bailing these financial problems out to store confidence on the Euro zone financial stability outlook.

Somaxon Announces FDA Approval of Silenor® (doxepin) for the Treatment of Insomnia

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor^® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

Sleep maintenance difficulty, defined as waking frequently during the night and/or waking too early and being unable to return to sleep, is the most commonly reported nighttime symptom of insomnia. Silenor is approved for the treatment of both transient (short term) and chronic (long term) insomnia characterized by difficulty with sleep maintenance in both adults and elderly patients. In clinical trials, Silenor demonstrated maintenance of sleep into the 7^th and 8^th hours of the night, with no meaningful evidence of next day residual effects.

The Britains got jobs in February surprising the market by 32.3k added jobs in a pace has not been seen since November 1997 while the market was waiting for losing .5k after a massive losing in January by 23.5k. The UK labor report of February has shown that the adjusted jobless claimant has come down to 4.9% while it was expected to be up to 5.1%. These optimistic data could push the British pound up across the broad. The cable rose more than  2 figures and half in less than an hour from 1.522 before the data triggering stop loses orders to 1.538 changing the market sentiment towards the British pound holding before retreating back during the day in a profit taken wave to 1.528 and it is now trying to hold above 1.53.